FI3529234T3 - Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon - Google Patents

Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon Download PDF

Info

Publication number
FI3529234T3
FI3529234T3 FIEP17865155.0T FI17865155T FI3529234T3 FI 3529234 T3 FI3529234 T3 FI 3529234T3 FI 17865155 T FI17865155 T FI 17865155T FI 3529234 T3 FI3529234 T3 FI 3529234T3
Authority
FI
Finland
Prior art keywords
benzimidazol
ethyl
ethoxy
methoxy
acetamide
Prior art date
Application number
FIEP17865155.0T
Other languages
English (en)
Finnish (fi)
Inventor
Werneck Guimarães Cristiano Ruch
Zaneti De Azevedo Hatylas Felype
Alessandra Mascarello
Da Costa Renata Watanabe
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Application granted granted Critical
Publication of FI3529234T3 publication Critical patent/FI3529234T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP17865155.0T 2016-10-24 2017-10-23 Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon FI3529234T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (1)

Publication Number Publication Date
FI3529234T3 true FI3529234T3 (fi) 2023-12-28

Family

ID=62023150

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17865155.0T FI3529234T3 (fi) 2016-10-24 2017-10-23 Yhdiste, menetelmä yhdisteen saamiseksi, faramseuttinen koostumus, yhdisteiden käyttö ja menetelmä psykiatristen häiriöiden ja/tai unihäiriöiden hoitoon

Country Status (20)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN110088092B (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES2970546T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20250558A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG11201903113TA (enExample)
UY (2) UY37334A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
CR20190379A (es) 2017-01-30 2019-10-21 Astrazeneca Ab Moduladores del receptor de estrógeno
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
US20210330653A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
WO1995034304A1 (en) * 1994-06-10 1995-12-21 Nauchno-Issledovatelsky Institut Farmakologii Rossiyskoi Akademii Meditsinskikh Nauk Pharmacologically active 2-mercaptobenzimidazole derivatives
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
PT1189900E (pt) 1999-06-30 2004-05-31 Bristol Myers Squibb Co Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos
WO2003062224A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP1719761A4 (en) 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
JP2010503654A (ja) * 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
JP2010507664A (ja) * 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Also Published As

Publication number Publication date
AU2017351756A1 (en) 2019-05-09
US11091445B2 (en) 2021-08-17
CN110088092B (zh) 2022-10-04
MX392990B (es) 2025-03-24
EP3741760C0 (en) 2024-12-04
CL2019001105A1 (es) 2019-09-06
BR102016024814A2 (pt) 2018-05-08
WO2018076090A1 (en) 2018-05-03
EP3529234A1 (en) 2019-08-28
EP3741760B1 (en) 2024-12-04
AR109467A1 (es) 2018-12-12
US10781182B2 (en) 2020-09-22
SG11201903113TA (en) 2019-05-30
DK3529234T3 (da) 2024-02-05
AU2017351756B2 (en) 2022-01-27
EP3529234B1 (en) 2023-11-29
PE20250558A1 (es) 2025-02-24
CN115181108A (zh) 2022-10-14
ECSP19032963A (es) 2019-05-31
MX2019004782A (es) 2019-10-09
PE20191046A1 (es) 2019-08-06
JP2019537624A (ja) 2019-12-26
US20190270711A1 (en) 2019-09-05
UY40644A (es) 2024-02-29
KR102594251B1 (ko) 2023-10-25
EP3529234A4 (en) 2020-03-11
CN110088092A (zh) 2019-08-02
ES3013994T3 (en) 2025-04-16
SG10202009001TA (en) 2020-10-29
US20200277265A1 (en) 2020-09-03
UY37334A (es) 2018-04-30
BR112019008197A2 (pt) 2019-07-16
ES2970546T3 (es) 2024-05-29
PT3529234T (pt) 2024-02-01
EP3741760A1 (en) 2020-11-25
CA3042040A1 (en) 2018-05-03
CO2019004756A2 (es) 2019-05-21
KR20190066023A (ko) 2019-06-12
JP7194683B2 (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
CN102341378B (zh) 1-烷基-5-苯甲酰基-1h-四唑衍生物的制备方法
JP2019532079A5 (enExample)
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
JP2018511647A5 (enExample)
JP2019519587A5 (enExample)
JP2020523381A5 (enExample)
JP2005501841A5 (enExample)
CN1074766C (zh) 烷氨基苯并噻唑及-苯并噁唑衍生物
JP2019537624A5 (enExample)
WO2013030100A1 (de) Verfahren zur herstellung von tetrazol-substituierten anthranilsäurediamid-derivaten durch umsetzung von benzoxazinonen mit aminen
JP2012149082A5 (enExample)
JP2015509966A5 (enExample)
DE60317632T2 (de) 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten
JP2005528341A5 (enExample)
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
FR3062850A1 (fr) Procede de preparation monotope de composes organo-iodes
CN1261420C (zh) 具有杀虫活性的噻唑衍生物的制备方法
CN86100282A (zh) N,n-二代羧酸酰胺类的制造方法
MY131847A (en) Improved method for making nevirapine
CN1809543A (zh) 杀线虫的含噻唑啉的氟代丁烯
JP2008524323A (ja) 新規なベンゾチアゾールカルボキサミド
JP2012214427A (ja) 1,2−ベンズイソチアゾリン−3−オンを含有する水性組成物の製造方法
CN1626520A (zh) 具有杀菌活性的α-(吡唑甲酸基)乙酰苯胺类化合物
Kim et al. Synthesis of 3-aminoindole derivatives: combination of Thorpe–Ziegler cyclization and unexpected allylindium-mediated decyanation
Tian et al. Synthesis and bioactivity of N-cyclopropanecarboxyl-N′-pyridin-2-yl thiourea derivatives and related fused ring compounds